Digital Commons Network^™

Lifelong Learning—It’S Not For Just The Old Folks Anymore!, John Bird, Teaching And Learning Center

The Weekly Reader

No abstract provided.

Rwu Faculty Member Andrew Rhyne Named Finalist In Wildlife Crime Tech Challenge, Public Affairs, Roger Williams University

Featured News Story

Rhyne is a contender for the People’s Choice Award and a $500,000 grand prize for creating real-time data analytics platform to enhance the detection of illegal wildlife trade.

11-02-2015 Swosu Biology Group Helps With Inventory At Bioblitz, Southwestern Oklahoma State University

THE BARK ARCHIVE 2015

The Southwestern Oklahoma State University Department of Biology recently participated in the 14th annual Oklahoma BioBlitz at Osage Hills State Park near Pawhuska.

Gsu View, 2015-11-02, Office Of Marketing And Communications

GSU View

Newsletter published by Governors State University 2007-current.

Monitoring Intracellular Component Pools To Identify Steady State In Mammalian Cell Perfusion Culture, Daniel Karst, Robert Steinhoff, Marie Kopp, Renato Zenobi, Massimo Morbidelli, Miroslav Soos

Integrated Continuous Biomanufacturing II

Perfusion cultures of mammalian cells are a well-considered alternative in the process development for new biologic products. Stable operation of the culture should eventually lead to a steady state, positively effecting product quality. Although macroscopic variables such as viable cell density, main metabolite or product concentrations are observed constant, little is known about the extent of steady state on intracellular level.

In this study intracellular component pools of CHO cells were monitored at different steady states in perfusion cultures using matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS). A novel single extraction was used to separate metabolite, …

Biosc® Predict Simulation Software: Flexibility And Optimization Of Your Multi-Column Process, Fabien Rousset

Integrated Continuous Biomanufacturing II

For a few years now, the biopharma industry has started implementing continuous processing, and more specifically continuous chromatography, to improve process economics together with process control and understanding. A simulation / optimization software has been developed to benefit from modelization by accommodating batch process data to multicolumn processes with associated optimal operating costs and reduced footprint. The presentation will highlight how the flexibility of the BioSC® and its simulation software BioSC® Predict is used to optimize affinity, ion exchange and isocratic processes in order to decrease media and buffer consumption and save lab operating time.

Medium Optimization Case Study For Continuous Upstream Process, Rashmi Kshirsagar, Alan Gilbert

Integrated Continuous Biomanufacturing II

Based on other mature industries, continuous upstream process is a logical replacement for current fed batch operations. However most industrial medium development has focused on the biological requirements for fed batch and therefore focused on the needs of stationary phase production. There is not an a priori expectation that growth and stationary phase requirements are identical. Yet an ideal continuous upstream process requires some combination of both. An optimal continuous upstream process requires a high cell density similar to fed batch operations. There is also some minimum growth rate required in order to match the combined death and cell removal …

A Novel Plant Cell Culture Platform For Semicontinous Production Of Recombinant Proteins: Butyrylcholinesterase As A Case Study, Jasmine Corbin, Bryce Hashimoto, Kalimuthu Karuppanan, Raymond Rodriguez, Somen Nandi, Brian Roberts, Amy Noe, Karen Mcdonald

Integrated Continuous Biomanufacturing II

In this paper we describe a novel biomanufacturing production platform that utilizes transgenic rice cell suspension cultures for efficient semicontinuous cell culture (SCC) production of recombinant proteins. The production platform utilizes a metabolically regulated promoter, a secretion signal peptide that enables secretion out of the cell for ease of recovery/purification, coupled with an efficient semicontinuous operational strategy that allows independent optimization of growth and production phases. In addition, long term operation (up several months¹) is possible by maintaining viable biomass within the bioreactor, thereby reducing the need for long seed trains, as well as minimizing turn-around time, CIP …

Evaluation Of Novel Cex Resin For Continous Processing Of Mab Purification, Takuya Muramoto, Satoshi Murakami, Shinsuke Higuchi, Keiji Iwamoto

Integrated Continuous Biomanufacturing II

We have evaluated novel cation exchange resin and membrane which is potentially suited for continuous process in biologics manufacturing.

Typically cation exchange chromatography (CEX) is used in a bind/elute (B/E) mode for the MAb process since MAb act as cation at the buffer condition used for CEX due to the pI from neutral to weak basic. Generally, purpose of CEX chromatography is to remove aggregates and other impurities like HCP and DNA. Especially, aggregate removal is of interest to the industries. A continuous process in MAb downstream process can solve several bottlenecks in typical batch process. However its capability cannot …

What Are The Facility Design Requirements To Fit Biologics Pipeline Demands?, Thomas Sauer

Integrated Continuous Biomanufacturing II

Decisions to install new facilities are typically driven by pipeline or capacity demands. While extensions to existing capacity typically restrict the level of freedom to design, this is different for pipeline products. Due to numerous unknowns in the development of drug candidates in a pipeline, maintaining a large degree of flexibility in future facility design is the most widely accepted de-risking concept. Looking more closely into the development of a biologics pipeline, certain elements help to control and limit the design space while others just effectuate the opposite.

Without question the key guiding principle for these future products is to …

Factors Affecting The Productivity Of 4-Column Periodic Counter Current Chromatography (4c-Pcc), Hani El-Sabbahy, Laura Fagan, Verity Nancollis

Integrated Continuous Biomanufacturing II

The advantages of continuous bioprocessing include steady state operation, reduced equipment footprint, high volumetric productivity, streamlined process flow, and reduced capital cost. These benefits have led to considerable interest in evaluating these technologies for the purposes of bioprocess intensification (Konstantinov & Cooney, 2014). It has been shown, through cost of goods modelling, that the cost of protein A is one of the most significant costs in a MAb process, and that decreasing the cost of protein A by maximising loading or increasing lifetime will have a significant effect on consumable costs (Broly, et al., 2010). Consequently, the application of continuous …

Novel Compact Cell Settlers For Continuous Perfusion Bioreactor Cultures Of Microbial (And Mammalian) Cells, Dhinakar Kompala, Brian Batt

Integrated Continuous Biomanufacturing II

About 25 years ago, we first demonstrated the use of inclined settlers for selective removal of dead cells and cell debris and complete recycle of live and productive cells back to perfusion bioreactors with murine hybridoma cells (Batt et al., 1990) and Chinese hamster ovary cells (Searles et al., 1994). These devices have been scaled up as lamellar settlers (Probstein and Yung, 1979) and applied successfully over the last two decades for commercial manufacture of several therapeutic biologics in high cell density continuous perfusion bioreactor cultures of recombinant mammalian cells by different biotech companies. However, the rectilinear scale up of …

Inline Spiking For Viral Clearance Validation Of Continuous Processes, Herb Lutz

Integrated Continuous Biomanufacturing II

Conventional clearance validation employs batch spiking using a uniform feed. In continuous processing, the feed to a unit operation can vary over the course of processing. An example would be an elution peak from an upstream step where the salt and protein concentrations vary over the course of operation. Batch spiking would not represent manufacturing practice in this case. Employment of inline spiking allows a scale down version of changing feed to be used for spiking studies. This talk will describe the qualification and application of the inline spiking method with a virus filter.

Enabling Technologies For Integrated / Continuous Downstream Processing Of Biologics, Jeff Salm, Marcus Fiadeiro, Raquel Orozco, Jill Kublbeck, Aaron Noyes, Jeff Horne, Daniel Lacasse, Ashley Sacramo, Suhani Gupta, John Coffman, Robert Fahrner

Integrated Continuous Biomanufacturing II

Pfizer Bioprocessing R&D is focused on developing enabling technologies that will reduce capital and operational expenses, decrease equipment scale, increase automation and utilize fewer FTEs.

To realize this vision, Purification Process Development has piloted new technologies and operational strategies that have enabled a fully integrated downstream process. Our current work has demonstrated a continuous process that includes tangential flow filtration harvest from a perfusion bioreactor, Protein A capture, inline viral inactivation/conditioning and AEX polishing. This process was fully automated and demonstrated at the 100 L scale. We have also shown feasibility of multi-day virus reduction filter operation and a continuous …

Design Criteria And Requirements For Development Of Perfusion Media, Jochen Sieck

Integrated Continuous Biomanufacturing II

There is increasing interest in perfusion processing as a means for increasing overall yield of the upstream process, facilitating a reduction of manufacturing costs. However, as in many companies the focus was on fed-batch process development for decades, hands-on knowledge about medium development for perfusion processes is considered a key gap for the wider adoption of perfusion processing in biologics manufacturing today.

Compared to batch-based cultivation, perfusion processes have fundamentally different requirements and challenges in terms of medium composition. The continuous nature of perfusion processes allows to achieve steady-state, although not all practitioners consider this desirable. The main challenge in …

Optimal Control Of A Continuous Bioreactor For Maximized Beta-Carotene Production, Nazmul Karim, Jonathan Raftery, Xinghua Pan

Integrated Continuous Biomanufacturing II

Carotenes such as β-carotene have a positive impact in human health as a precursor of vitamin A. Structural complexity of these compounds makes their chemical synthesis a difficult endeavor, facilitating the need for their biological production. Continuous operation can be used in these processes to allow for increased cell viability through the mitigation of substrate and product inhibition, thereby increasing the productivity of the carotenoid product. This work looks to examine the operating conditions necessary to achieve the maximum production of the desired carotenoid products when produced via continuous operation. First, a two-level parameter estimation method is utilized to develop …

Integrated And Single Use Continuous Manufacturing, Atul Mohindra

Integrated Continuous Biomanufacturing II

Continuous processing for biopharmaceutical production is attracting considerable interest within the industry. The concept of continuous processing is not new and the value of continuous manufacturing has been well documented for decades across the steel, chemicals and food industries. Despite the vast differences between product types, the advantages of continuous over batch production remain consistent and include steady state operation, high volumetric productivity, streamlined process flow and reduced capital costs.

Over the past decade, significant investments have already been made with continuous bio-manufacturing development. The need for the biopharmaceutical industry to follow suit is being influenced by a number of …

Pilot Scale Hybrid Fed Batch And Continuous Processing Of Biologics, Dave Sullivan, Michael O'Connor, Samir Gondalia, Matt Gagnon

Integrated Continuous Biomanufacturing II

Pfizer Bioprocessing R&D is focused on developing enabling technologies that will reduce capital and operational expenses, decrease equipment scale, increase automation and utilize fewer FTEs. To realize this vision, our Pilot Facility has partnered with our cell culture process development colleagues to adapt a fed batch platform 150L stainless steel bioreactor to run in hybrid perfusion, standard perfusion, low volume cell controlled perfusion, and continuous stirred tank modes. Through adjustments to impeller configuration, sparging strategy, and addition ports the bioreactor was able to deliver multiple batches that produced ~3X gains in cell density and volumetric productivity versus conventional fed batch …

Continuous Downstream Process Or Connected Batch Process: Which One Makes Most Sense For Biogen?, John Pieracci, Sanchayita Ghose, Venkatesh Natarajan

Integrated Continuous Biomanufacturing II

As biologics-based products move into therapeutic areas with large patient populations and high doses, batch processing may not be able to keep pace with product demands. At Biogen, we have been exploring a number of options that can enable higher productivity of our downstream processes. In addition to a fully “end to end” continuous process, a batch process comprised of several steps connected in series has been evaluated. In this presentation, technologies Biogen has evaluated to enable either continuous or connected processing will be shown. Multi-Column-Chromatography (MCC) for the Protein A capture chromatography step was evaluated in order to maximize …

Development Of Functionally Closed Downstream Operations For Continuous Biomanufacturing Of Recombinant Therapeutic Proteins, Rohan Patil, Rahul Godawat, Tarl Vetter, Yogesh Waghmare, Konstantin Konstantinov, Veena Warikoo

Integrated Continuous Biomanufacturing II

Traditionally, upstream processing in biologics manufacturing is performed in an aseptic and functionally closed manner while downstream processes are open operations designed to maintain a low-bioburden state. Consequently, the downstream process components such as skids, column hardware, and chromatography resins currently available have been designed for low bioburden rather than aseptic operations. One of the key design elements of Integrated Continuous Biomanufacturing (ICB) is the linkage of upstream and downstream operations and the capability of the system to run for prolonged durations at ambient temperature. Thus, a critical design criterion for ICB is the ability of the system to maintain …

Continuous Production Of Viral Vaccines With A Two-Stage Bioreactor System, Felipe Tapia, Yvonee Genzel, Ingo Jordan, Volker Sandig, Udo Reichl

Integrated Continuous Biomanufacturing II

Continuous processes can be particularly efficient for production of biologicals that are required in large amounts such as viral vaccines. One virus that has received much clinical attention is Modified Vaccinia Ankara virus (MVA), which is a potential platform for expression of recombinant viral antigens and can be used as a vector in gene therapy [1]. Recently, a new MVA virus strain has been successfully propagated at high yields in non-aggregated avian suspension cells [2] allowing the production of MVA virus in continuous bioreactors. MVA is a lytic DNA virus and therefore, continuous production strategies can be implemented using two-stage …

Strategy For Scaling Semi-Continuous Downstream And Integration Of Process Analytical Tools For Monoclonal Antibody Toxicology, Darshini Shah, Rebecca Chmielowski, Colette Cutler, Hong Li, David Roush, Nihal Tugcu

Integrated Continuous Biomanufacturing II

Currently, continuous processing for biologics is being pursued from a technology perspective in order to increase productivity and decrease cost of manufacture. Disruptive technologies, such as PCC (Periodic Counter-current Chromatography), have been researched extensively in order to reduce the bottleneck for the downstream capture chromatography step. However, there is extremely limited knowledge in how to scale these disruptive technologies for clinical and commercial manufacturing. In this presentation, we demonstrate a strategy for scaling and integration of a PCC capture step into a semi-continuous downstream process (Protein A chromatography-Viral inactivation-Filtration-Anion exchange chromatography). Harvest cell culture fluid (HCCF) feed streams ranging from …

Scale Up And Implementation Of A High Density Long-Term Perfusion Suspension Cell Culture In A 250l Single Use Bioreactor, Weichang Zhou, Hang Zhou

Integrated Continuous Biomanufacturing II

As part of efforts to develop a continuous processing platform for biologics manufacturing using a single use bioreactor, we have been focusing on development of several initial unit operations: high density perfusion suspension cell cultures and early product capture steps, in order to realize its potentials of being flexible, improving product quality and lowering costs. These initial unit operations require large volumes and represent the most important part of this processing platform. By integrating these steps into a continuous operation, we can deliver the largest benefits of this processing platform. In this presentation, we will discuss our efforts towards continuous …

The Tiger Vol. 109 Issue 46 2015-11-02, Clemson University

Tiger Newspapers 2015

No abstract provided.

Current, November 02, 2015, University Of Missouri-St. Louis

Current (2010s)

No abstract provided.

Grand Valley Forum, Volume 040, Number 10, November 02, 2015, Grand Valley State University

2015-2016, Volume 40

Grand Valley Forum is Grand Valley State's faculty and staff newsletter, published from 1976 to the present.

Optical Enzymatic Sensors For Continuous Monitoring Of Bioreactors, Kenneth Reardon, Brian Heinze, Trenton Danna

Integrated Continuous Biomanufacturing II

Continuous monitoring of biotechnological processes is important for control and optimization of quality and productivity. Typically, samples must be removed from the cultivation and analyzed in a laboratory to determine the concentrations of substrates and products. These time-delayed data cannot be used for real-time process control. The Process Analytical Technology initiative of the FDA supports the use of on-line measurement techniques for process development, production, and quality. An overview of sensors will be presented, focusing on in-situ sensors that contact the biological medium, and external sensors that contact the medium either optically (ex situ) or via a sterile (and disposable) …

Salt-Tolerant Cation Exchange Hd-Sb Hydrogel Membrane: Mab Purification Performance In Flowthrough Mode, Dharmesh Kanani, Daniel Luo, Nirali Paghdal, Navneet Sidhu, Annabel Shang, Jim Stout

Integrated Continuous Biomanufacturing II

Development of Protein A based purification platforms have simplified the downstream processing of monoclonal antibodies (mAb), the largest component of biopharmaceuticals. The ever increasing titer of the cell culture process is putting more pressure on the downstream process to further increase its productivity. The classical Protein A based mAb purification platform consists of two polishing steps, bind and elute cation-exchanger and flowthrough anion-exchanger. Cation-exchange chromatography is very efficient at the separation of HCP, leached Protein A and product-related impurities such as aggregates and fragments in bind and elute mode. However, anion-exchange chromatography is a proven technology to remove DNA, viruses, …

Designing A Microbial Cultivation Platform For Continuous Biopharmaceutical Production, Nicholas Mozdzierz, Kerry Love, Alan Stockdale, John Clark, Noelle Colant, Christopher Love

Integrated Continuous Biomanufacturing II

The existing biopharmaceutical manufacturing paradigm is poorly suited to produce biologic drugs on demand at a point-of-care. Generally, commercial-scale (~2,000 - 10,000 L) manufacturing using fed-batch cultivation and fixed stainless-steel infrastructure is concentrated in developed nations and results in process cycle times on the order of weeks to months.^1,2 Coupled with the complex logistical challenges associated with continuous “plant-to-patient” cold-chains, the geographically biased nature of therapeutic protein production today can limit access to biologic drugs in developing areas of the world.³ There is an opportunity to create technologies capable of rapidly generating biopharmaceuticals in situ in emergency situations, …

Pbio Colloquium | Predicting Plant Responses To Climate Change, Dec. 8, Ohio University College Of Arts & Sciences

All Forum Articles

No abstract provided.